{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:50:53Z","timestamp":1790391053557,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.semarthrit.2023.152211","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T11:26:07Z","timestamp":1683199567000},"page":"152211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Adherence to colchicine prophylaxis among patients with familial Mediterranean fever treated with interleukin-1 inhibitors"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5841-6664","authenticated-orcid":false,"given":"Yoel","family":"Levinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Azani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered","family":"Shkalim Zemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rotem","family":"Tal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liora","family":"Harel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Amarilyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2023.152211_bib0001","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrrheum.2011.94","article-title":"Genetics of monogenic autoinflammatory diseases: past successes, future challenges","volume":"7","author":"Aksentijevich","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152211_bib0002","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrrheum.2013.174","article-title":"A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin","volume":"10","author":"Ozen","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152211_bib0003","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.semarthrit.2013.04.011","article-title":"Evidence-based recommendations for the practical management of Familial Mediterranean fever","volume":"43","author":"Hentgen","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"16","key":"10.1016\/j.semarthrit.2023.152211_bib0004","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM198604173141601","article-title":"Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever","volume":"314","author":"Zemer","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152211_bib0005","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1542\/peds.2006-1434","article-title":"Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement","volume":"119","author":"Kallinich","year":"2007","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152211_bib0006","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","article-title":"Treating inflammation by blocking interleukin-1 in humans","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin Immunol"},{"key":"10.1016\/j.semarthrit.2023.152211_bib0007","first-page":"75","article-title":"Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature","volume":"10","author":"van der Hilst JCh","year":"2016","journal-title":"Biologics"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152211_bib0008","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3899\/jrheum.160518","article-title":"Longterm beneficial effect of canakinumab in colchicine-resistant familial mediterranean fever","volume":"44","author":"Laskari","year":"2017","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152211_bib0009","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/art.39995","article-title":"Anakinra for colchicine-resistant familial mediterranean fever: a randomized, double-blind, placebo-controlled trial","volume":"69","author":"Ben-Zvi","year":"2017","journal-title":"rthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152211_bib0010","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40266-013-0074-z","article-title":"Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature","volume":"30","author":"Sattler","year":"2013","journal-title":"Drugs Aging"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152211_bib0011","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bcp.13494","article-title":"Characterization of adherence and persistence profile in a real-life population of patients treated with adalimumab","volume":"84","author":"Gendelman","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2023.152211_bib0012","unstructured":"Points Location Intelligence [internet], general information. [cited 2022 october 10]. available from: https:\/\/points.co.il\/en\/points-location-intelligence\/."},{"key":"10.1016\/j.semarthrit.2023.152211_bib0013","series-title":"Characterization and classification of geographic units by the soci-economic level of the population publication no. 1530","year":"2013"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152211_bib0014","first-page":"995","article-title":"The role of amyloidosis in familial mediterranean fever. A population study","volume":"4","author":"Gafni","year":"1968","journal-title":"Isr J Med Sci"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152211_bib0015","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2020-217419","article-title":"Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial","volume":"79","author":"Ozen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152211_bib0016","unstructured":"Sheba medical center [internet], The FMF Division. [cited 2022 october 10]. available from: https:\/\/www.sheba.co.il\/heller."},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2023.152211_bib0017","doi-asserted-by":"crossref","first-page":"P81","DOI":"10.1186\/1546-0096-13-S1-P81","article-title":"Compliance to colchicine treatment and disease activity in Familial Mediterranean Fever (FMF) patients in Middle\/Black Sea Region of Turkey (in \u00c7orum region)","volume":"13","author":"Karaaslan","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152211_bib0018","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3906\/sag-2102-328","article-title":"Non-adherence to colchicine treatment is a common misevaluation in familial Mediterranean fever","volume":"51","author":"Tekg\u00f6z","year":"2021","journal-title":"Turk J Med Sci"},{"issue":"3\u20134","key":"10.1016\/j.semarthrit.2023.152211_bib0019","first-page":"78","article-title":"Cardiovascular sequelae and genetics of familial mediterranean fever: a literature review","volume":"8","author":"Malik","year":"2021","journal-title":"Pulse"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152211_bib0020","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s11606-015-3285-7","article-title":"Reductions in use of colchicine after FDA enforcement of market exclusivity in a commercially insured population","volume":"30","author":"Kesselheim","year":"2015","journal-title":"J Gen Intern Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152211_bib0021","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semarthrit.2017.03.006","article-title":"Colchicine resistance and intolerance in familial mediterranean fever: definition, causes, and alternative treatments","volume":"47","author":"Ozen","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152211_bib0022","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1542\/peds.2006-1434","article-title":"Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement","volume":"119","author":"Kallinich","year":"2007","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152211_bib0023","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40258-013-0078-1","article-title":"A systematic review of osteoporosis medication adherence and osteoporosis-related fracture costs in men","volume":"12","author":"Mikyas","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152211_bib0024","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11096-014-9929-6","article-title":"The association between the measurement of adherence to anti-diabetes medicine and the HbA1c","volume":"36","author":"Doggrell","year":"2014","journal-title":"Int J Clin Pharm"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152211_bib0025","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/MLR.0b013e31817924d2","article-title":"An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients","volume":"46","author":"Karve","year":"2008","journal-title":"Med Care"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152211_bib0026","doi-asserted-by":"crossref","first-page":"117","DOI":"10.15386\/mpr-1201","article-title":"An overview of the common methods used to measure treatment adherence","volume":"92","author":"Anghel","year":"2019","journal-title":"Med Pharm Rep"},{"key":"10.1016\/j.semarthrit.2023.152211_bib0027","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/217047","article-title":"Medication adherence measures: an overview","volume":"2015","author":"Lam","year":"2015","journal-title":"Biomed Res Int"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152211_bib0028","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1093\/rheumatology\/keaa863","article-title":"Defining colchicine resistance\/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach","volume":"60","author":"\u00d6zen","year":"2021","journal-title":"Rheumatology (Oxford)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:10:41Z","timestamp":1758733841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223000537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":28,"alternative-id":["S0049017223000537"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152211","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence to colchicine prophylaxis among patients with familial Mediterranean fever treated with interleukin-1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152211"}}